ALLMedicine™ Prostate Cancer Center

Dec 4th, 2020 - We retrospectively analyzed Spinal Instability Neoplastic Score (SINS) in 110 patients with prostate cancer operated for metastatic spinal cord compression. We aimed to investigate the association between SINSs and clinical outcomes after surgery ...

Dec 4th, 2020 - Appreciable findings have pointed out pivotal roles of N 6-methyladenosine (m6A) machinery in cancer onset and progression. However, limited efforts have been directed towards relevant research in the prostate cancer area. A PubMed search was cond...

Dec 4th, 2020 - Patients with advanced prostate cancer (PCa) frequently develop skeletal metastases that are associated with fractures, disability, and increased mortality. Within the bone metastatic niche, mutual interactions between tumor cells and osteoblasts ...

Dec 4th, 2020 - Prostate cancer (PCa), one of the most commonly diagnosed cancers worldwide, still presents important unmet clinical needs concerning treatment. In the last years, the metabolic reprogramming and the specificities of tumor cells emerged as an exci...

Dec 3rd, 2020 - The optimal treatment for oligorecurrent prostate cancer (PCa) is a matter of debate. We aimed to assess oncologic outcomes of patients treated with metastasis-directed therapy (MDT) vs. androgen deprivation therapy (ADT) for oligorecurrent PCa. W...

Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Jul 21st, 2020 - Although substantial literature examining the neuropsychiatric consequences of androgen deprivation therapy (ADT) exists, there are no clinical guidelines to inform providers about the specific risk of depression, suicide, and dementia for prostat...

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achiev...

Jun 30th, 2020 - Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Parker C,Castro E,Fizazi K,Heidenreich A,Ost P,|

May 31st, 2020 - Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and was superior to leuprolide in sustained testosterone suppression, testoste...

Dec 4th, 2020 - We retrospectively analyzed Spinal Instability Neoplastic Score (SINS) in 110 patients with prostate cancer operated for metastatic spinal cord compression. We aimed to investigate the association between SINSs and clinical outcomes after surgery ...

Dec 4th, 2020 - Appreciable findings have pointed out pivotal roles of N 6-methyladenosine (m6A) machinery in cancer onset and progression. However, limited efforts have been directed towards relevant research in the prostate cancer area. A PubMed search was cond...

Dec 4th, 2020 - Patients with advanced prostate cancer (PCa) frequently develop skeletal metastases that are associated with fractures, disability, and increased mortality. Within the bone metastatic niche, mutual interactions between tumor cells and osteoblasts ...

Dec 4th, 2020 - Prostate cancer (PCa), one of the most commonly diagnosed cancers worldwide, still presents important unmet clinical needs concerning treatment. In the last years, the metabolic reprogramming and the specificities of tumor cells emerged as an exci...

Dec 3rd, 2020 - The optimal treatment for oligorecurrent prostate cancer (PCa) is a matter of debate. We aimed to assess oncologic outcomes of patients treated with metastasis-directed therapy (MDT) vs. androgen deprivation therapy (ADT) for oligorecurrent PCa. W...

Dec 1st, 2020 - A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for institutional use at the University of California,...

Dec 1st, 2020 - NEW YORK (Reuters Health) - Long-term androgen-deprivation therapy (ADT) is associated with worse cardiorespiratory fitness (CRF) and higher cardiovascular (CV) mortality in prostate cancer (PC) patients with high CV risk at baseline, new research...

Dec 1st, 2020 - As the fifth most common cause of cancer death in men worldwide, prostate cancer is largely identified in patients who are asymptomatic. For the most part, prostate cancer-related deaths occur as a result of advanced disease, which results from an...

Nov 30th, 2020 - An increase in the risk of falling and fracturing bones was associated with the use of androgen receptor inhibitors (ARIs) for the treatment of prostate cancer, a systematic review and meta-analysis suggests. "We know from this meta-analysis that ...

Nov 17th, 2020 - Routinely collected clinical data help identify men with high-risk prostate cancer most likely to benefit from a gallium-68 prostate-specific membrane antigen (PSMA) PET/CT scan, according to a study reported at the American Society for Radiation ...